Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Xenetic Biosciences (XBIO) Stock Price

News headlines about Xenetic Biosciences (NASDAQ:XBIO) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Xenetic Biosciences earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 49.0289134159306 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Xenetic Biosciences (NASDAQ XBIO) opened at $2.16 on Friday. Xenetic Biosciences has a 12 month low of $1.75 and a 12 month high of $5.90.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Wednesday, November 15th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). The business had revenue of $0.09 million during the quarter. sell-side analysts forecast that Xenetic Biosciences will post -0.89 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered Xenetic Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st.

TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://transcriptdaily.com/2017/12/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-xenetic-biosciences-xbio-stock-price.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Insider Buying and Selling by Quarter for Xenetic Biosciences (NASDAQ:XBIO)

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply